John Oyler, Chief Executive Officer at BeOne Medicines Ltd. (ONC), sold 64,628 shares at $305.20 ($20.2M) on 2026-07-17, disclosed to the SEC on 2026-07-17.
Scheduled sale ($20.2M) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $305.20 | 1,440 | $439K | 2.2% |
| 2 | $306.96 | 597 | $183K | 0.9% |
| 3 | $309.05 | 680 | $210K | 1.0% |
| 4 | $310.37 | 4,833 | $1.5M | 7.4% |
| 5 | $311.42 | 5,543 | $1.7M | 8.6% |
| 6 | $312.17 | 35,829 |
| $11.2M |
| 55.5% |
| 7 | $313.19 | 14,915 | $4.7M | 23.2% |
| 8 | $314.32 | 740 | $233K | 1.2% |
| 9 | $315.06 | 51 | $16K | 0.1% |
| Total | $312.00 avg | 64,628 | $20.2M | 100% |
| Filing → |
| ONC | SELL | 2026-07-17 | $89.4M | — | Filing → |
| ONC | SELL | 2026-07-14 | $18.3M | — | Filing → |
| ONC | SELL | 2026-07-14 | $44.6M | — | Filing → |